Susan C. Modesitt, MD, FACOG, FACS, is professor and director of the Division of Gynecologic Oncology in the Department of Gynecology and Obstetrics at Emory University School of Medicine. Dr. Modesitt leads the gynecologic oncology program at Winship Cancer Institute of Emory University. A board certified gynecologic oncologist, Dr. Modesitt specializes in the treatment of gynecologic malignancies, and is an attending based primarily at Emory University Hospital Midtown and Emory University Hospital. Prior to joining Emory, she was professor and division director of gynecologic oncology at the University of Virginia.
Dr. Modesitt is a fellow of the American College of Obstetricians and Gynecologists and the American College of Surgeons and has served in multiple leadership roles and committees for Society of Gynecologic Oncology, American College of Obstetricians and Gynecologists, American Board of Obstetrics and Gynecology, and NRG Oncology.
Dr. Modesitt completed medical school at the University of Virginia in Charlottesville, her obstetrics and gynecology residency at the University of North Carolina in Chapel Hill and her gynecologic oncology fellowship at the M.D. Anderson Cancer Center.
Dr. Modesitt's research focuses on hereditary cancers, obesity-related cancers and clinical trials in gynecologic oncology.
Dr. Modesitt serves as editor-in-chief of Gynecologic Oncology Reports. She has published extensively on gynecologic cancers.
|
|
|
| Title/Journal | Authors | Publication Date |
|---|---|---|
|
Gynecologic oncology reports |
KA Roof, KE Andre, SC Modesitt, DA Schirmer | 06/01/2024 |
|
Gynecologic oncology reports |
TL Boitano, SC Modesitt | 02/01/2024 |
|
Communications medicine |
A Aggarwal, S Khalighi, D Babu, H Li, S Azarianpour-Esfahani, G Corredor, P Fu, M Mokhtari, T Pathak, E Thayer, S Modesitt, H Mahdi, S Avril, A Madabhushi | 01/03/2024 |
|
Gynecologic Oncology Reports: 2022 and beyond. Gynecologic oncology reports |
SC Modesitt | 06/01/2023 |
|
Condyloma lata mimicking vulvar carcinoma in an immunocompromised patient: A case report. Gynecologic oncology reports |
EG Thayer, ZA Roecker, KM Van Smaalen, MC Mason, SC Modesitt | 04/01/2023 |
|
Gynecologic oncology |
CA Thomson, TE Crane, A Miller, MA Gold, M Powell, K Bixel, L Van Le, P DiSilvestro, E Ratner, S Lele, S Guntupalli, W Huh, SE Robertson, S Modesitt, AC Casey, K Basen-Engquist, M Skiba, J Walker, L Kachnic, DS Alberts | 03/01/2023 |
|
Gynecologic oncology reports |
WN Goldsberry, BS Norquist, RP Rocconi, SC Modesitt, RR Urban | 12/01/2022 |
|
Obstetrics and gynecology |
KL Ring, AM Mills, SC Modesitt | 12/01/2022 |
|
Optimizing post-operative opiate prescribing following gynecologic surgery. Gynecologic oncology reports |
KM Croft, BM Sarosiek, E Trowbridge, C Page Muthusubramanian, T Hedrick, SC Modesitt | 08/01/2022 |
|
Ridiculously good writing: How to write like a pro and publish like a boss. Gynecologic oncology reports |
SC Modesitt, LJ Havrilesky, RA Previs, J Alejandro Rauh-Hain, J Michael Straughn, JN Bakkum-Gamez, KC Fuh, DE Cohn | 08/01/2022 |
|
American journal of obstetrics and gynecology |
PL Mai, A Miller, A Black, RT Falk, JF Boggess, K Tucker, AR Stuckey, GC Rodriguez, C Wong, TT Amatruda, KJ Wilkinson, SC Modesitt, SD Yamada, KL Bixel, GE Glaser, PG Rose, MH Greene, ME Sherman | 07/01/2022 |
Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.
| 4.9 | Provider showed concern | |
| 4.9 | Provider explained things clearly | |
| 4.9 | Provider discussed treatment options | |
| 4.9 | Provider included you in decisions | |
| 4.9 | Likelihood of recommending this provider |
